9,758 results match your criteria Parkinson Disease Dementia


Barriers and facilitators of communication about off periods in Parkinson's disease: Qualitative analysis of patient, carepartner, and physician Interviews.

PLoS One 2019 18;14(4):e0215384. Epub 2019 Apr 18.

Morton and Gloria Shulman Movement Disorders Centre and the Edmond J Safra Program in Parkinson's Research, Toronto Western Hospital, Toronto, Ontario, Canada.

Background: Successful patient-physician communication is critical for improving health outcomes, but research regarding optimal communication practices in Parkinson's disease is limited. The objective of the current study was to investigate barriers and facilitators of communication between persons with Parkinson's disease, carepartners, and physicians, specifically in the setting of off periods, with the goal of identifying ways to improve patient-carepartner-physician communication.

Method: We interviewed persons with Parkinson's, carepartners, and physicians (specialists and non-specialists) using a semi-structured questionnaire to identify and describe experiences, barriers, and facilitators relating to communication about off periods in Parkinson's disease. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0215384PLOS

Management of Dysphagia in Patients with Parkinson's Disease and Related Disorders.

Intern Med 2019 Apr 17. Epub 2019 Apr 17.

Department of Neurology, Kochi Medical School, Kochi University, Japan.

Various methods of rehabilitation for dysphagia have been suggested through the experience of treating stroke patients. Although most of these patients recover their swallowing function in a short period, dysphagia in Parkinson's disease (PD) and Parkinson-related disorder (PRD) degenerates with disease progression. Muscle rigidity and bradykinesia are recognized as causes of swallowing dysfunction, and it is difficult to easily apply the strategies for stroke to the rehabilitation of dysphagia in PD patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2169/internalmedicine.2373-18DOI Listing
April 2019
1 Read

Inflammation in Mild Cognitive Impairment due to Parkinson's disease, Lewy Body disease and Alzheimer's disease.

Int J Geriatr Psychiatry 2019 Apr 16. Epub 2019 Apr 16.

Institute of Neuroscience, Newcastle upon Tyne, United Kingdom.

Background: Inflammation appears to play a role in the progression of neurodegenerative diseases. However, little is known about inflammation during early stages of cognitive decline or whether this differs in different disease groups. We sought to investigate this by assessing the inflammatory profile in patients with Parkinson's disease with the early stages of cognitive impairment (PD-MCI), patients with prodromal Alzheimer's disease (MCI-AD), prodromal Lewy Body disease (MCI-LB) and controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gps.5124DOI Listing

Involvement of cortical dysfunction in frequent falls in patients with Parkinson's disease.

Parkinsonism Relat Disord 2019 Apr 11. Epub 2019 Apr 11.

Department of Neurology, Osaka University Graduate School of Medicine, Suita, Osaka, 565-0871, Japan. Electronic address:

Introduction: Gait and balance disorders are common clinical features of Parkinson's disease (PD). Although falls significantly affect the activities of daily living (ADL) and quality of life (QOL) of patients with PD, the underlying neural mechanisms associated with frequent falls in PD patients are still unclear.

Methods: Hypothesizing that the cerebral cortex would contribute to frequent falls in PD, we obtained 3D T1-weighted images from 91 non-dementia patients with PD and performed voxel-based morphometric analysis (VBM). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.04.007DOI Listing

No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors.

Transl Neurodegener 2019 3;8:11. Epub 2019 Apr 3.

1Department of Neurology, University Hospital Schleswig Holstein, Arnold-Heller Str. 3, 24105 Kiel, Germany.

Background: IgG-class autoantibodies to N-Methyl-D-Aspartate (NMDA)-type glutamate receptors define a novel entity of autoimmune encephalitis. Studies examining the prevalence of NMDA IgA/IgM antibodies in patients with Parkinson disease with/without dementia produced conflicting results. We measured NMDA antibodies in a large, well phenotyped sample of Parkinson patients without and with cognitive impairment ( = 296) and controls ( = 295) free of neuropsychiatric disease. Read More

View Article

Download full-text PDF

Source
https://translationalneurodegeneration.biomedcentral.com/art
Publisher Site
http://dx.doi.org/10.1186/s40035-019-0153-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6446289PMC
April 2019
1 Read

Electrocortical networks in Parkinson's disease patients with Mild Cognitive Impairment. The PaCoS study.

Parkinsonism Relat Disord 2019 Apr 3. Epub 2019 Apr 3.

Department "G.F. Ingrassia", Section of Neurosciences, University of Catania, Via S. Sofia 78, 95123, Catania, Italy. Electronic address:

Introduction: Parkinson's Disease (PD) is frequently associated with cognitive dysfunction ranging from Mild Cognitive Impairment (PD-MCI) to dementia. Few electrophysiological studies are available evaluating potential pathogenetic mechanisms linked to cognitive impairment in PD since its initial phases. The objective of the study is to analyze electrocortical networks related with cognitive decline in PD-MCI for identifying possible early electrophysiological markers of cognitive impairment in PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.03.027DOI Listing

Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease.

Front Neurol 2019 22;10:266. Epub 2019 Mar 22.

IRCCS San Camillo Hospital, Venice, Italy.

Impulse control disorders (ICDs) and related behaviors are frequent in Parkinson's disease (PD). Mild cognitive impairment (PD-MCI) and dementia (PDD), both characterized by heterogeneous cognitive phenotypes, are also commonly reported in PD. However, the frequency and severity of ICD within PD cognitive states is unknown. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00266DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6439312PMC
March 2019
1 Read

Neurofilament light chain as a biomarker in neurological disorders.

J Neurol Neurosurg Psychiatry 2019 Apr 9. Epub 2019 Apr 9.

Institute of Neuroscience and Physiology Department of Psychiatry and Neurochemistry, The Sahlgrenska AcademyUniversity of Gothenburg, Mölndal, Sweden.

In the management of neurological diseases, the identification and quantification of axonal damage could allow for the improvement of diagnostic accuracy and prognostic assessment. Neurofilament light chain (NfL) is a neuronal cytoplasmic protein highly expressed in large calibre myelinated axons. Its levels increase in cerebrospinal fluid (CSF) and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including inflammatory, neurodegenerative, traumatic and cerebrovascular diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2018-320106DOI Listing
April 2019
2 Reads

LRP10 in autosomal-dominant Parkinson's disease.

Mov Disord 2019 Apr 9. Epub 2019 Apr 9.

Department of Neurology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Background: Recently, the LRP10 gene has been identified as a novel genetic cause in individuals affected by Parkinson's disease (PD), Parkinson's disease dementia, or dementia with Lewy bodies.

Objective: We investigated the involvement of LRP10 mutations in Chinese patients with familial PD and reviewed previous studies of LRP10 mutations in patients with PD.

Methods: A mutation analysis of the LRP10 gene was performed in a cohort of 205 unrelated Chinese patients with familial PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27693DOI Listing

Effects of Mindfulness Yoga vs Stretching and Resistance Training Exercises on Anxiety and Depression for People With Parkinson Disease: A Randomized Clinical Trial.

JAMA Neurol 2019 Apr 8. Epub 2019 Apr 8.

The Nethersole School of Nursing, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong Special Administrative Region.

Importance: Clinical practice guidelines support exercise for patients with Parkinson disease (PD), but to our knowledge, no randomized clinical trials have tested whether yoga is superior to conventional physical exercises for stress and symptom management.

Objective: To compare the effects of a mindfulness yoga program vs stretching and resistance training exercise (SRTE) on psychological distress, physical health, spiritual well-being, and health-related quality of life (HRQOL) in patients with mild-to-moderate PD.

Design, Setting, And Participants: An assessor-masked, randomized clinical trial using the intention-to-treat principle was conducted at 4 community rehabilitation centers in Hong Kong between December 1, 2016, and May 31, 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamaneurol.2019.0534DOI Listing
April 2019
1 Read

Most cases with Lewy pathology in a population-based cohort adhere to the Braak progression pattern but 'failure to fit' is highly dependent on staging system applied.

Parkinsonism Relat Disord 2019 Mar 28. Epub 2019 Mar 28.

Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA; Parkinson's Disease Research, Education and Clinical Center, Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, PA, USA. Electronic address:

Braak et al.'s 2003 paper detailing the caudo-rostral progression of Lewy body pathology (LP) formed the foundation of current understanding of disease spread in Parkinson's disease (PD); however, its methods are difficult to recreate and consequently multiple new staging systems emerged to recapitulate Braak's staging system using standard neuropathological methods and to account for other patterns of LP. Studies using these systems have documented widely variable rates of cases that 'fail to fit' expected patterns of LP spread. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.03.023DOI Listing
March 2019
1 Read

Mild cognitive impairment reverters have a favorable cognitive prognosis and cortical integrity in Parkinson's disease.

Neurobiol Aging 2019 Mar 11;78:168-177. Epub 2019 Mar 11.

Department of Neurology, Yonsei University College of Medicine, Seoul, South Korea; Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, South Korea. Electronic address:

This study aimed to investigate whether reversion to cognitively normal status (CogN) is related to a favorable cognitive prognosis in Parkinson's disease with mild cognitive impairment (PD-MCI). We recruited 217 patients with PD-MCI who underwent serial neuropsychological assessments 3-5 times (mean interval, 1.84 years). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurobiolaging.2019.02.023DOI Listing
March 2019
2 Reads

Higher probability of prodromal Parkinson disease is related to lower cognitive performance.

Neurology 2019 Apr 3. Epub 2019 Apr 3.

From the 1st Department of Neurology (A.B., E.N., C.A.A., L.S., N.S.), Aiginition Hospital, National and Kapodistrian, University of Athens Medical School; Department of Nutrition and Dietetics (M.I.M., M.Y., E.N., C.A.A.), Harokopio University; Parkinson's Disease and Movement Disorders Department (M.S.), Hygeia Hospital, Athens, Greece; Department of Neurology (M.S.), Philipps University, Marburg, Germany; School of Medicine (G.X., E.D., G.M.H.), University of Thessaly, Larissa; Laboratory of Cognitive Neuroscience, School of Psychology (M.H.K.), Aristotle University of Thessaloniki, Greece; Department of Neurology (G.M.H.), Medical School, University of Cyprus; Athens Association of Alzheimer's Disease and Related Disorders (E.N., P.S.), Maroussi; Center of Clinical, Experimental Surgery and Translational Research (L.S.), Biomedical Research Foundation of the Academy of Athens, Greece; and Taub Institute for Research in Alzheimer's Disease and the Aging Brain (N.S.), The Gertrude H. Sergievsky Center, Department of Neurology, Columbia University, New York, NY.

Objective: Given the limited information on cognitive function before Parkinson disease (PD) clinical onset in the general population, we sought to assess prodromal PD (pPD) probability and relate it to detailed cognitive performance in a community cohort.

Methods: In a population-based cohort of 1,629 dementia-free and PD-free participants ≥65 years of age in Greece, we assessed probability of pPD according to the International Parkinson and Movement Disorder Society's criteria. Clinical cognitive diagnoses (cognitively unimpaired, mild cognitive impairment [MCI], dementia) considering neuropsychological testing and functional status were assigned in consensus conferences. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007453DOI Listing
April 2019
13 Reads

Association of statin use with Parkinson's disease: Dose-response relationship.

Mov Disord 2019 Apr 2. Epub 2019 Apr 2.

Department of Family Medicine/Supportive Care Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

Background: There have been conflicting results on the association between statin use and Parkinson's disease (PD) incidence.

Objectives: This study investigated the association between time-varying status of statin use and incidence of PD while considering the dose-response relationship and total cholesterol level.

Methods: Using the database of the Korean National Health Insurance Service from 2002 to 2015, we examined 76,043 subjects (≥60 years old) free of PD, dementia, and stroke at baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27681DOI Listing
April 2019
2 Reads

Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and α-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study.

Parkinsonism Relat Disord 2019 Mar 23. Epub 2019 Mar 23.

Sleep Medicine Centre, Department of Systems Medicine, University of Rome 'Tor Vergata", Rome, Italy.

Introduction: Several longitudinal studies revealed that patients affected by idiopathic REM behavior disorder (iRBD) trend to convert to α-synucleinopathies at follow-up, although the time and direction of conversion is currently unpredictable. This study aimed at evaluating brain glucose metabolism, measured by [18F]FDG-PET, in patients affected by iRBD and compared to Parkinson's Disease (PD), Lewy Body Dementia (DLB), Alzheimer's Disease (AD), and controls.

Methods: Differences in brain [18F]FDG uptake were analyzed using statistical parametric mapping implemented in Matlab R2012b among iRBD, PD, DLB, AD, and controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.03.017DOI Listing
March 2019
1 Read

A proteomic signature for dementia with Lewy bodies.

Alzheimers Dement (Amst) 2019 Dec 15;11:270-276. Epub 2019 Mar 15.

Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.

Introduction: We sought to determine if a proteomic profile approach developed to detect Alzheimer's disease would distinguish patients with Lewy body disease from normal controls, and if it would distinguish dementia with Lewy bodies (DLB) from Parkinson's disease (PD).

Methods: Stored plasma samples were obtained from 145 patients (DLB n = 57, PD without dementia n = 32, normal controls n = 56) enrolled from patients seen in the Behavioral Neurology or Movement Disorders clinics at the Mayo Clinic, Florida. Proteomic assays were conducted and analyzed as per our previously published protocols. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S23528729193000
Publisher Site
http://dx.doi.org/10.1016/j.dadm.2019.01.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424013PMC
December 2019
3 Reads

Lysosomal enzyme activities as possible CSF biomarkers of synucleinopathies.

Clin Chim Acta 2019 Mar 25;495:13-24. Epub 2019 Mar 25.

Laboratory of Clinical Neurochemistry, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy. Electronic address:

Mutations on the GBA gene, encoding for the lysosomal enzyme β-glucocerebrosidase (GCase), have been identified as the most common genetic risk factor involved in the development of Parkinson's disease (PD) and dementia with Lewy bodies (DLB), indicating a direct contribution of this enzyme to the pathogenesis of synucleinopathies. Decreased GCase activity has been observed repeatedly in brain tissues and biological fluids of both GBA mutation carrier and non-carrier PD and DLB patients, suggesting that lower GCase activity constitutes a typical feature of these disorders. Additional genetic, pathological and biochemical data on other lysosomal enzymes (e. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.cca.2019.03.1627DOI Listing
March 2019
1 Read

Prodromal Parkinson's Disease: The Decade Past, the Decade to Come.

Mov Disord 2019 Mar 28. Epub 2019 Mar 28.

Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany.

The past decade has seen a dramatic expansion of the field of prodromal PD. Ten years ago, there were only six known prodromal markers of disease, none of which had more than two studies documenting diagnostic value. We now have at least 16 markers, with as many as 10 prospective studies for a single marker. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27670DOI Listing
March 2019
1 Read

Dementia and Parkinson's Disease: Similar and Divergent Challenges in Providing Palliative Care.

Front Neurol 2019 11;10:54. Epub 2019 Mar 11.

Department of Primary and Community Care, Radboud university medical center, Nijmegen, Netherlands.

Dementia and Parkinson's disease are incurable neurological conditions. Patients often experience specific, complex, and varying needs along their disease trajectory. Current management typically employs a multidisciplinary team approach. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00054DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6421983PMC
March 2019
1 Read

Mild cognitive impairment in Parkinson's disease: Characterization and impact on quality of life according to subtype.

Geriatr Gerontol Int 2019 Mar 25. Epub 2019 Mar 25.

Movement Disorders Section, Neurology Department, Pedro Ernesto University Hospital, State University of Rio de Janeiro, Rio de Janeiro, Brazil.

Aim: Mild cognitive impairment (MCI) was initially described as a risk factor for Alzheimer's disease. Because of differences in baseline cognitive abilities, MCI in Parkinson's disease (PD; PD-MCI) requires distinct neuropsychological criteria for diagnosis and follow up. In addition to representing a risk factor for PD-related dementia, PD-MCI results in higher morbidity, which can be reduced through early detection. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ggi.13649DOI Listing
March 2019
1 Read

Cognitive profiles and optimal cut-offs for routine cognitive tests in elderly individuals with Parkinson's disease, Parkinson's disease dementia, Alzheimer's disease, and normal cognition.

Psychogeriatrics 2019 Mar 25. Epub 2019 Mar 25.

Department Internal Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.

Aim: The cognitive impairment seen in Parkinson's disease (PD) results in patient disability and reduced quality of life. However, using cognitive screening scales specific to PD in routine clinical practice is difficult because of limited time, resources, and skills. We studied the ability of routine cognitive tests to differentiate between Parkinson's disease dementia (PDD) and PD and among the neuropsychological profiles of elderly individuals with PD, PDD, Alzheimer's disease (AD), and normal cognition. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/psyg.12451DOI Listing
March 2019
3 Reads

Pharmacokinetics and pharmacodynamics of a single dose Nilotinib in individuals with Parkinson's disease.

Pharmacol Res Perspect 2019 04 12;7(2):e00470. Epub 2019 Mar 12.

Translational Neurotherapeutics Program Laboratory for Dementia and Parkinsonism Department of Neurology Georgetown University Medical Center Washington District of Columbia.

Nilotinib is a broad-based tyrosine kinase inhibitor with the highest affinity to inhibit Abelson (c-Abl) and discoidin domain receptors (DDR1/2). Preclinical evidence indicates that Nilotinib reduces the level of brain alpha-synuclein and attenuates inflammation in models of Parkinson's disease (PD). We previously showed that Nilotinib penetrates the blood-brain barrier (BBB) and potentially improves clinical outcomes in individuals with PD and dementia with Lewy bodies (DLB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prp2.470DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6412143PMC
April 2019
4 Reads

Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease.

Front Neurol 2019 8;10:195. Epub 2019 Mar 8.

Department of Neurology, Jena University Hospital, Jena, Germany.

Parkinson's disease is a common multisystem neurodegenerative disorder characterized by typical motor and non-motor symptoms. There is an urgent need for biomarkers for assessment of disease severity, complications and prognosis. In addition, biomarkers reporting the underlying pathophysiology assist in understanding the disease and developing neuroprotective therapies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00195DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6418014PMC
March 2019
8 Reads

Dysphagia predicts poor outcome in late-stage Parkinson's disease.

Parkinsonism Relat Disord 2019 Mar 2. Epub 2019 Mar 2.

Instituto de Medicina Molecular, Lisbon, Portugal; Laboratory of Clinical Pharmacology and Therapeutics, Faculdade de Medicina, Universidade de Lisboa, Portugal; CNS - Campus Neurológico Sénior, Torres Vedras, Portugal. Electronic address:

Background: Few data exist on the rate of clinical progression for Parkinson's disease (PD) patients who have entered a late stage of the disease.

Objective: Study the clinical progression of a late-stage PD (LSPD) population over one year follow-up.

Methods: 50 LSPD patients (Schwab and England ADL Scale <50 or Hoehn Yahr Stage >3 in MED ON) underwent an extensive clinical assessment at baseline and after one year and an acute levodopa test at baseline. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.02.043DOI Listing
March 2019
1 Read

Clinical, pathophysiological and genetic features of motor symptoms in autosomal dominant Alzheimer's disease.

Brain 2019 Mar 20. Epub 2019 Mar 20.

German Center for Neurodegenerative Diseases (DZNE), Munich, Germany.

Owing to an early and marked deposition of amyloid-β in the basal ganglia, autosomal dominant Alzheimer's disease could distinctly involve motor symptoms. Therefore, we aimed to assess the prevalence and characteristics of motor signs in autosomal dominant Alzheimer's disease. Baseline Unified Parkinson Disease Rating Scale part three scores (UPDRS-III) from 433 participants of the Dominantly Inherited Alzheimer's Network observational study were analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/awz050DOI Listing
March 2019
3 Reads
9.196 Impact Factor

Cognitive Problems in Parkinson Disease: Perspectives and Priorities of Patients and Care Partners.

Cogn Behav Neurol 2019 03;32(1):16-24

Department of Neurology, Division of Neuropsychology, Baylor Scott & White Health, Temple, Texas.

Objective: To report how people with Parkinson disease (pwPD) and their care partners (CPs) describe the cognitive impacts of the disease, explore the convergent validity of subjective cognitive complaints (SCCs) with measures of cognition and daily functioning, and report the cognitive treatment priorities of pwPD and their CPs.

Background: Cognitive symptoms in pwPD are common and disabling. Although objective cognitive impairments have been closely studied, SCCs are less well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WNN.0000000000000184DOI Listing
March 2019
1 Read

Clinical and neuropathological differences between Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies - current issues and future directions.

J Neurochem 2019 Mar 20. Epub 2019 Mar 20.

Institute of Neuroscience, Campus for Ageing and Vitality, Newcastle University, Newcastle-upon-Tyne, NE4 5PL, UK.

Lewy body diseases (LBDs) share clinical, pathological, genetic, and biochemical signatures, and are regarded as a highly heterogeneous group of neurodegenerative disorders. Inclusive of Parkinson's disease (PD), Parkinson's disease dementia (PDD), and dementia with Lewy bodies (DLB), controversy still exists as to whether they should be considered as separate disease entities or as part of the same disease continuum. Here we discuss emerging knowledge relating to both clinical, and neuropathological differences and consider current biomarker strategies as we try to improve our diagnostic capabilities and design of disease modifying therapeutics for this group of debilitating neurodegenerative disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jnc.14698DOI Listing
March 2019
1 Read

Striatal DAT and extrastriatal SERT binding in early-stage Parkinson's disease and dementia with Lewy bodies, compared with healthy controls: An I-FP-CIT SPECT study.

Neuroimage Clin 2019 Mar 12;22:101755. Epub 2019 Mar 12.

Amsterdam UMC, Vrije Universiteit Amsterdam, Psychiatry, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands; Amsterdam UMC, Vrije Universiteit Amsterdam, Anatomy and Neurosciences, Amsterdam Neuroscience, De Boelelaan 1117, Amsterdam, Netherlands.

Parkinson's disease (PD) and dementia with Lewy bodies (DLB) are thought to be part of a spectrum: both have a clinical profile including symptoms associated with dopaminergic and serotonergic loss, yet few imaging studies have focused on serotonergic neurodegeneration in both disorders. We aimed to study degeneration of terminals with dopamine and serotonin transporter (DAT and SERT, respectively) in patients with early-stage PD and DLB relative to healthy controls, using I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (I-FP-CIT) single photon emission computed tomography (SPECT). We conducted region of interest (ROI) and voxel-based analyses on I-FP-CIT SPECT scans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nicl.2019.101755DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6424141PMC
March 2019
1 Read

Therapeutic potentials of plant iridoids in Alzheimer's and Parkinson's diseases: A review.

Eur J Med Chem 2019 May 8;169:185-199. Epub 2019 Mar 8.

Department of Chemistry, Dasaratha Deb Memorial College, Khowai, Tripura, 799201, India.

Alzheimer's disease (AD) and Parkinson's disease (PD) are the most common age-related neurodegenerative disorders, affecting several millions of aged people globally. Among these disorders, AD is more severe, affecting about 7% of individuals aged 65 and above. AD is primarily a dementia-related disorder from progressive cognitive deterioration and memory impairment, while PD is primarily a movement disorder illness having three major kinesia or movement disorder symptoms, bradykinesia (slowness of movements), hypokinesia (reduction of movement amplitude), and akinesia (absence of normal unconscious movements) along with muscle rigidity and tremor at rest. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejmech.2019.03.009DOI Listing
May 2019
11 Reads

Modifiable risk factors for cognitive impairment in Parkinson's disease: A systematic review and meta-analysis of prospective cohort studies.

Mov Disord 2019 Mar 14. Epub 2019 Mar 14.

Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College, Fudan University, Shanghai, China.

Background: Cognitive impairment is a common and devastating manifestation in Parkinson's disease (PD). We aimed to identify modifiable risk factors for PD with cognitive impairment.

Methods: We systematically searched PubMed and the Cochrane Library from June 1937 to September 2018 and included prospective cohort studies with random-effects model used to combine estimates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27665DOI Listing
March 2019
4 Reads

Current treatment of behavioral and cognitive symptoms of Parkinson's disease.

Authors:
Irena Rektorova

Parkinsonism Relat Disord 2019 Feb 28. Epub 2019 Feb 28.

Movement Disorders Centre, First Department of Neurology, Faculty of Medicine, St. Anne's University Hospital, Masaryk University, Brno, Czech Republic; Applied Neuroscience Research Group, Central European Institute of Technology, CEITEC MU, Masaryk University, Brno, Czech Republic. Electronic address:

Cognitive and behavioral symptoms are common in Parkinson's disease, may occur even in the prodromal stages of the disease, worsen with disease progression, and surpass motor symptoms as the major factors affecting patient quality of life and caregiver burden. The symptoms may be caused by the disease pathology or they may represent adverse effects of treatment, or both etiological factors may contribute. Although many of these symptoms are related to dopaminergic dysfunction or dopaminergic medication, other neurotransmitters are involved as well. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2019.02.042DOI Listing
February 2019
2 Reads

Stroke Research With Longitudinal Cohort Studies.

Authors:
Hugo J Aparicio

Stroke 2019 Apr;50(4):e103-e105

From the Department of Neurology, Boston University School of Medicine, MA; and Framingham Heart Study, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1161/STROKEAHA.118.023790DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433522PMC
April 2019
3 Reads

Goal management training ® home-based approach for mild cognitive impairment in Parkinson's disease: a multiple baseline case report.

Neurocase 2019 Mar 1:1-11. Epub 2019 Mar 1.

a School of Psychology , Laval University , Quebec City , Canada.

Approximately 30% of patients with Parkinson's disease experience mild cognitive impairment (PD-MCI), often affecting executive functions. Our objective was to assess tolerability, safety and preliminarily efficacy of Goal Management Training® (GMT) for PD-MCI. GMT was administered at home, for five weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13554794.2019.1583345DOI Listing
March 2019
1 Read
1.381 Impact Factor

Validity and reliability of the Persian version of the Montreal Cognitive Assessment (MoCA-P) scale among subjects with Parkinson's disease.

Appl Neuropsychol Adult 2019 Mar 1:1-9. Epub 2019 Mar 1.

f Cognitive Neurology & Neuropsychiatry Division, Department of Psychiatry , School of Medicine, Tehran University of Medical Sciences , Tehran , Iran.

Parkinson's disease (PD) is a progressive multifactorial degenerative disorder that has both motor and nonmotor features. Among the nonmotor features of PD, cognitive impairment; Mild Cognitive Impairment (MCI) and dementia, poses one of the most significant implications for disability. Because of the high possibility of developing Dementia in PD, it is essential to obtain a reliable cognitive screen. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/23279095.2019.1565762DOI Listing
March 2019
3 Reads

Diffuse Lewy body disease.

J Neurol Sci 2019 Apr 20;399:144-150. Epub 2019 Feb 20.

The Truong Neuroscience Institute, Orange Coast Memorial Medical Center, Fountain Valley, CA, USA; Departments of Psychiatry and Neuroscience, UC Riverside, Riverside, CA, USA. Electronic address:

Diffuse Lewy body disease, also called dementia with Lewy bodies (DLB), is defined as progressive dementia and pathological Lewy bodies distributed in the central and autonomic nervous systems. The clinical features are dementia, cognitive fluctuations, visual hallucinations, parkinsonism, and REM sleep behavior disorder (RBD). Confirmatory techniques include dopamine transporter imaging, meta-iodobenzylguanidine (MIBG) myocardial scintigraphy, and polysomnography. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.02.021DOI Listing

Levodopa-induced dyskinesia is closely linked to progression of frontal dysfunction in PD.

Neurology 2019 Mar 22;92(13):e1468-e1478. Epub 2019 Feb 22.

From the Department of Neurology (H.S.Y., S.J.C., Y.H.L., B.S.Y., Y.H.S., P.H.L.), Severance Biomedical Science Institute (P.H.L.), and Biostatistics Collaboration Unit (H.S.L), Yonsei University College of Medicine, Seoul, South Korea.

Objective: To assess the relationship between the development of levodopa-induced dyskinesia (LID) and longitudinal changes in cognition.

Methods: In this retrospective cohort study, we recruited 119 patients with Parkinson disease (PD) who underwent baseline and follow-up neuropsychological evaluations and were treated with levodopa for >5 years. On the basis of LID development, the patients were classified as patients with LID (PD-LID+, n = 38) or without LID (PD-LID-, n = 81) within 5 years of levodopa administration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0000000000007189DOI Listing
March 2019
1 Read
8.286 Impact Factor

Sequence- and seed-structure-dependent polymorphic fibrils of alpha-synuclein.

Biochim Biophys Acta Mol Basis Dis 2019 Feb 18. Epub 2019 Feb 18.

Laboratory of Structural Neuropathology, Doshisha University Graduate School of Brain Science, 1-3 Miyakodanitatara, Kyotanabe-shi, Kyoto 610-0394, Japan. Electronic address:

Synucleinopathies comprise a diverse group of neurodegenerative diseases including Parkinson's disease (PD), dementia with Lewy bodies, and multiple system atrophy. These share a common pathological feature, the deposition of alpha-synuclein (a-syn) in neurons or oligodendroglia. A-syn is highly conserved in vertebrates, but the primary sequence of mouse a-syn differs from that of human at seven positions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.bbadis.2019.02.013DOI Listing
February 2019

PINK1 Interacts with VCP/p97 and Activates PKA to Promote NSFL1C/p47 Phosphorylation and Dendritic Arborization in Neurons.

eNeuro 2018 Nov-Dec;5(6). Epub 2018 Jan 10.

Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213.

While PTEN-induced kinase 1 (PINK1) is well characterized for its role in mitochondrial homeostasis, much less is known concerning its ability to prevent synaptodendritic degeneration. Using unbiased proteomic methods, we identified valosin-containing protein (VCP) as a major PINK1-interacting protein. RNAi studies demonstrate that both VCP and its cofactor NSFL1C/p47 are necessary for the ability of PINK1 to increase dendritic complexity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/ENEURO.0466-18.2018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377406PMC
March 2019
5 Reads

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta-analysis.

Exp Ther Med 2019 Mar 24;17(3):1611-1624. Epub 2018 Dec 24.

Department of Neurology, Hebei General Hospital, Shijiazhuang, Hebei 050051, P.R. China.

Recently, several randomized controlled trials on the use of cholinesterase inhibitors or memantine as treatments for cognitive impairment in Parkinson's disease (CIND-PD), Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) were completed. The present study provided a meta-analysis of these studies to evaluate the efficacy of cholinesterase inhibitors and memantine on CIND-PD, PDD and DLB. The Cochrane Library, Pubmed, Embase and Web of Science databases were searched to retrieve eligible studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/etm.2018.7129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6364145PMC

Long-term outcomes of deep brain stimulation in Parkinson disease.

Nat Rev Neurol 2019 Apr;15(4):234-242

Department of Clinical and Movement Neurosciences, University College London, Queen Square Institute of Neurology, London, UK.

The efficacy of deep brain stimulation (DBS) for Parkinson disease (PD) is well established for up to 1 or 2 years, but long-term outcome data are still limited. In this Review, we critically discuss the evidence on the long-term outcomes of DBS and consider the clinical implications. Although many patients are lost to follow-up, the evidence indicates that subthalamic nucleus DBS improves motor function for up to 10 years, although the magnitude of improvement tends to decline over time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41582-019-0145-9DOI Listing
April 2019
5 Reads

Comparative sensitivity of the MoCA and Mattis Dementia Rating Scale-2 in Parkinson's disease.

Mov Disord 2019 Feb 10;34(2):285-291. Epub 2018 Dec 10.

Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.

Background: Clinicians and researchers commonly use global cognitive assessments to screen for impairment. Currently there are no published studies directly comparing the sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. The objective of this study was to identify the relative sensitivity and specificity of the Montreal Cognitive Assessment and Mattis Dementia Rating Scale-2 in PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27575DOI Listing
February 2019
5 Reads

Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features.

Mov Disord 2019 Apr 17;34(4):568-574. Epub 2019 Feb 17.

Department of Neurology, Juntendo University School of Medicine, Tokyo, Japan.

Background: While mechanistic links between tau abnormalities and neurodegeneration have been proven in frontotemporal dementia and parkinsonism linked to chromosome 17 caused by MAPT mutations, variability of the tau pathogenesis and its relation to clinical progressions in the same MAPT mutation carriers are yet to be clarified.

Objectives: The present study aimed to analyze clinical profiles, tau accumulations, and their correlations in 3 kindreds with frontotemporal dementia and parkinsonism linked to chromosome 17 attributed to the MAPT N279K mutation.

Methods: Four patients with N279K mutant frontotemporal dementia and parkinsonism linked to chromosome 17/MAPT underwent [ C]PBB3-PET to estimate regional tau loads. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mds.27623DOI Listing
April 2019
4 Reads

Polysomnographic data in Dementia with Lewy Bodies: correlation with clinical symptoms and comparison with other α-synucleinopathies.

Sleep Med 2019 Mar 18;55:62-68. Epub 2018 Dec 18.

Department of Neurology, Hospital de Egas Moniz, Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal; CEDOC, Chronic Diseases Research Center, NOVA Medical School, USA.

Introduction: Sleep dysfunction is frequent in Dementia with Lewy Bodies (DLB), but polysomnographic (PSG) data is scarce. Our objectives were to: (1) compare PSG data between DLB patients and age normative values (NV), Parkinson's Disease (PD) and idiopathic REM sleep behavior disorder (iRBD) patients; (2) evaluate the relation between of OSA, Fluctuations and Hypersomnolence and PSG data.

Methods: We selected all consecutive patients with DLB, PD and iRBD that underwent video-PSG during a two year period. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.sleep.2018.12.006DOI Listing
March 2019
6 Reads

Continuing pharmacy education practices in geriatric care among pharmacists in the Upper Midwest.

J Am Pharm Assoc (2003) 2019 Feb 13. Epub 2019 Feb 13.

Objectives: To summarize select continuing pharmacy education (CPE) topics and hours related to geriatric care completed by community, hospital/clinic, and long-term care (LTC)/consultant pharmacists in the previous 12 months, whether pharmacy workplace influenced topic selection or completion, and to describe CPE sources used by community versus hospital/clinic pharmacists.

Design: Cross-sectional survey (2017).

Setting And Participants: Licensed pharmacists in North Dakota, South Dakota, Minnesota, Iowa, and Nebraska with primary practice settings in community pharmacies, hospitals, or clinics or those practicing as consultant pharmacists. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.japh.2018.12.020DOI Listing
February 2019
1 Read

Abnormal α-synuclein deposits in skin nerves: intra- and inter-laboratory reproducibility.

Eur J Neurol 2019 Feb 15. Epub 2019 Feb 15.

Philipps University, Marburg, Germany.

Background: Visualization of phosphorylated α-synuclein at serine 129 (p-syn) in skin nerves is a promising test for the in vivo diagnosis of synucleinopathies. Here we aimed to establish the intra- and inter-laboratory reproducibility of quantification of intraneural p-syn immunoreactivity in two laboratories with a major expertise (Würzburg and Bologna).

Methods: We enrolled 43 patients affected by Parkinson's disease (PD: 21 patients), Dementia with Lewy Body (DLB: 1), REM sleep behavior disorder (RBD: 11), Multiple System Atrophy (MSA-P: 4) and small fiber neuropathy (SFN: 6). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.13939DOI Listing
February 2019
1 Read

A case-control-family study of idiopathic rapid eye movement sleep behavior disorder.

Ann Neurol 2019 Apr 19;85(4):582-592. Epub 2019 Mar 19.

Sleep Assessment Unit, Department of Psychiatry, Faculty of Medicine, Chinese University of Hong Kong, Shatin, Hong Kong, China.

Objective: To determine the familial aggregation of idiopathic rapid eye movement sleep behavior disorder (iRBD), neurodegenerative diseases, and related biomarkers.

Methods: A total of 404 and 387 first-degree relatives of 102 patients with iRBD and of 89 controls were recruited, respectively. Among them, 204 and 208 relatives of patients and controls underwent face-to-face clinical assessment, whereas 97 and 75 relatives underwent further video-polysomnographic assessment, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.25435DOI Listing
April 2019
12 Reads

Neurologic Conditions: Parkinson Disease.

FP Essent 2019 Feb;477:16-21

University of South Alabama College of Medicine Department of Family Medicine, 1601 Center Street, 2N Mobile, AL 36604.

Parkinson disease (PD) is a complex neurologic disorder that involves motor and nonmotor brain functions. PD is the second most common neurodegenerative disease after Alzheimer disease. Motor symptoms include resting tremor, cogwheel rigidity, extreme slowness of movement, shuffling gait, and impaired balance. Read More

View Article

Download full-text PDF

Source
February 2019
1 Read

COWAT Performance of Persons With Alzheimer's Dementia, Vascular Dementia, and Parkinson's Disease Dementia According to Stage of Cognitive Impairment.

PM R 2019 Feb 12. Epub 2019 Feb 12.

Department of Physical Medicine and Rehabilitation, Ilsan Paik Hospital, Inje University, Goyang, South Korea.

Background: The Controlled Oral Word Association Test (COWAT) evaluates frontal lobe and executive function. Therefore, it can be helpful in differentiating cognitive deficits. However, there are no studies comparing the COWAT performance according to the type and stage of cognitive impairment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/pmrj.12125DOI Listing
February 2019
4 Reads

MIBG Myocardial Scintigraphy Identifies Premotor PD/DLB During a Negative DAT Scan Period: Second Report.

Mov Disord Clin Pract 2019 Jan 9;6(1):46-50. Epub 2018 Nov 9.

Gastroenterology, Internal Medicine, Sakura Medical Center Toho University Sakura Japan.

Objectives: Neuroimaging markers for Parkinson's disease (PD)/dementia with Lewy bodies (DLB) include dopamine transporter (DAT) scanning and metaiodobenzylguanidine (MIBG) myocardial scintigraphy. It is unknown which marker is useful to identify the premotor phase PD/DLB. We reported four patients who, during a negative DAT scan period, had a positive MIBG result that suggested premotor PD/DLB. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/mdc3.12697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6335543PMC
January 2019
2 Reads

Neural correlates of distinct cognitive phenotypes in early Parkinson's disease.

J Neurol Sci 2019 Apr 7;399:22-29. Epub 2019 Feb 7.

University of California San Diego, Department of Neurosciences, La Jolla, CA, USA.

Objective: Cognitive decline is common in Parkinson's disease (PD), but changes can occur in a variety of cognitive domains. The lack of a single cognitive phenotype complicates diagnosis and tracking. In an earlier study we used a data-driven approach to identify distinct cognitive phenotypes of early PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2019.02.013DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6436969PMC
April 2019
2 Reads